Although this research is not directly related to retinopathy, Murakami et al. found that pemafibrate and sodium-glucose cotransporter 2 (SGLT2) inhibitor combination treatment improves pathological progression in an experimental rodent model of non-alcoholic steatohepatitis [70]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.